Travere Therapeutics Inc (NASDAQ:TVTX) currently has a daily average trading volume of 1.38M but it saw 2787298 shares traded in last market. With a market cap of 2.02B USD, the company’s current market price of $23.20 came falling about -2.32 while comparing to the previous closing price of $23.75. In past 52 weeks, the stock remained buoying in the range of price level as high as $25.29 and as low as $5.12. In the recent trading on the day, stock has struck highest price mark of $22.6178 while lowest mark touched by it was $24.23.
Taking a look at 20-day trading activity of Travere Therapeutics Inc (TVTX) gives us an average price of $20.62, while its current price level is -8.26% below from 52-week high level whereas it is 353.13% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $19.16 while that of 200 days or SMA-200 reads an average of $13.31. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.34% during that period while stretching the period over a month that decreases to 6.18%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 66.05 which implies that the stock is in neutral territory.
Wells Fargo upgraded its recommendation for the stock as a “Overweight” from “Equal Weight” on October 21, 2024 while assigning a price target range of $9-$27.
Over the week, TVTX’s stock price is moving 9.38% up while it is 24.80% when we observe its performance for the past one month. Year-to-date it is 33.18% up and over the past year, the stock is showing an upside performance of 173.58%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -0.38 while estimate for next year EPS is -2.85. In next quarter, company is expected to be making quarterly sales of $71.66M as analysts are expecting the sales for current fiscal year at $230.88M and seeing the company making $335.72M in sales next year. Moreover, analysts are in estimates of $72.38M for current-quarter revenue.
Currently, Travere Therapeutics Inc’s total number of outstanding shares is 87.03M with 0.65% of that held by the insiders while 99.68% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -117.93% and return on equity (ROE) at -279.94%. Stock’s beta reads 0.75. Stock has a price to sale or P/S ratio amounts to 9.92. Its return on asset (ROA) is -52.19% on average.